孟鲁司特钠联合沙丁胺醇和BiPAP无创通气治疗重度支气管哮喘的效果分析

Curative Effect of Montelukast Sodium Combined with Salbutamol and BiPAP Non-invasive Ventilation in the Treatment of Severe Bronchial Asthma

目的:探讨孟鲁司特钠联合沙丁胺醇和BiPAP无创通气治疗重度支气管哮喘的临床效果。方法:选取2019年1月-2021年1月信宜市人民医院收治的68例重度支气管哮喘患者,按照数字表法分为两组,每组34例。试验组采用孟鲁司特钠+沙丁胺醇+BiPAP无创通气治疗,对照组采用沙丁胺醇+BiPAP无创通气治疗。比较两组用药不良反应及治疗后临床症状与肺功能改善情况,评价疗效与安全性。结果:试验组临床症状改善时间为喘息(3.74±1.25)d,哮鸣音(4.62±1.19)d,咳嗽(5.11±0.95)d,均早于对照组,差异有统计学意义(P<0.05)。试验组治疗总有效率为97.06%,高于对照组,差异有统计学意义(P<0.05)。试验组治疗后第1秒用力呼气容积(FEV;)为(3.25±0.59)L,用力肺活量(FVC)为(3.86±0.48)L,最大呼气峰流速(PEF)为(7.26±0.76)L/s,均优于对照组,差异均有统计学意义(P<0.05)。两组用药期间均未见相关不良反应。结论:孟鲁司特钠联合沙丁胺醇和BiPAP无创通气治疗重度支气管哮效果确切,可以更好地改善患者临床症状与肺功能,应用安全有效。

Objective:To explore the clinical effect of Montelukast Sodium combined with Salbutamol and BiPAP non-invasive ventilation in the treatment of severe bronchial asthma.Method:A total of 68 patients with severe bronchial asthma admitted to Xinyi City People’s Hospital from January 2019 to January 2021 were selected,they were divided into two groups according to the number table method,with 34 patients in each group.The experimental group was treated with Montelukast Sodium + Salbutamol + BiPAP non-invasive ventilation,while the control group was treated with Salbutamol + BiPAP non-invasive ventilation.The adverse drug reactions,clinical symptoms and improvement of lung function were compared between two groups,and the efficacy and safety were evaluated.Result:The improvement time of clinical symptoms in the experimental group was gasp (3.74±1.25) d,wheezing (4.62±1.19) d,cough (5.11±0.95) d,which were earlier than those in the control group,the differences were statistically significant (P<0.05).The total effective rate of the experimental group was 97.06%,which was higher than that of the control group,the difference was statistically significant (P<0.05).The forced expiratory volume in one second (FEV;),forced vital capacity (FVC) and maximum expiratory peak flow rate (PEF) of the experimental group were (3.25±0.59) L,(3.86±0.48) L and (7.26±0.76) L/s after treatment,which were better than those of the control group,and the differences were statistically significant (P<0.05).There were no related adverse reactions in two groups.Conclusion:Montelukast Sodium combined with Salbutamol and BiPAP non-invasive ventilation has a definite effect in the treatment of severe bronchial asthma,which can better improve the clinical symptoms and lung function of patients,and the application is safe and effective.